Narges Golab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Narges Golab has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Masoumeh Beig
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
3 shared publications- Mohammad Sholeh
Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
3 shared publications Elaheh Ebrahimi
Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsAbbas Zare Banadkouki
Department of Microbiology, Shahid Beheshti University, Tehran, Iran
1 shared publicationBehzad Naghash
International Laboratories of Dr Kamkar, Tehran, Iran
1 shared publicationElnaz Parvizi
Department of Microbiology, Science and Research Branch, Islamic Azad University, Fars, Iran
1 shared publication
Latest Publications
- Open Access
- 16 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0311124
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations. Methods: We systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE. Quality assessment was performed using the JBI checklist. Subgroup analyses were performed based on the COVID-19 timeframes, years, countries, continents, and bias levels, antimicrobial susceptivity test method and guidelines. Results: Our comprehensive meta-analysis, which included 795 studies across 80 countries from 1995 to 2023, revealed a surge in carbapenem resistance among A. baumannii, imipenem (76.1%), meropenem (73.5%), doripenem (73.0%), ertapenem (83.7%), and carbapenems (74.3%). Temporally, 2020–2023 witnessed significant peaks, particularly in carbapenems (81.0%) and meropenem (80.7%), as confirmed by meta-regression, indicating a steady upward trend. Conclusion: This meta-analysis revealed an alarmingly high resistance rate to CRAB as a global challenge, emphasizing the urgent need for tailored interventions. Transparency, standardized methodologies, and collaboration are crucial for the accurate assessment and maintenance of carbapenem efficacy.
- 16 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0311124
Open AccessGeographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations. Methods: We systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE. Quality assessment was performed using the JBI checklist. Subgroup analyses were performed based on the COVID-19 timeframes, years, countries, continents, and bias levels, antimicrobial susceptivity test method and guidelines. Results: Our comprehensive meta-analysis, which included 795 studies across 80 countries from 1995 to 2023, revealed a surge in carbapenem resistance among A. baumannii, imipenem (76.1%), meropenem (73.5%), doripenem (73.0%), ertapenem (83.7%), and carbapenems (74.3%). Temporally, 2020–2023 witnessed significant peaks, particularly in carbapenems (81.0%) and meropenem (80.7%), as confirmed by meta-regression, indicating a steady upward trend. Conclusion: This meta-analysis revealed an alarmingly high resistance rate to CRAB as a global challenge, emphasizing the urgent need for tailored interventions. Transparency, standardized methodologies, and collaboration are crucial for the accurate assessment and maintenance of carbapenem efficacy.
- Open Access
- 2 December 2024
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 18 (12) , e0012630
Unravelling the challenge of cotrimoxazole and rifampin resistance in B. melitensis and B. abortus: A systematic review and meta-analysis
Background: Brucellosis caused by Brucella (B. abortus) and Brucella melitensis (B. melitensis) poses a significant threat to human and animal populations. The World Health Organization (WHO) recommends rifampin and cotrimoxazole as first-line treatments for pediatric brucellosis. However, emerging resistance to these antibiotics raises concerns regarding their continued efficacy. This systematic review and meta-analysis aimed to quantitatively assess the prevalence of rifampin and cotrimoxazole resistance in B. abortus and B. melitensis. Methods: Eligible studies were identified by systematically searching various databases, such as Scopus, PubMed, Web of Science, and EMBASE databases, using specified search terms until 18 June 2024. The inclusion criteria required studies in English to report the resistance proportion with sample size details. The meta-analysis utilized a random-effects model to assess heterogeneity using the Q-test and I2 statistic. Meta-regression and subgroup analyses explored temporal, geographical, and guideline-related variations in resistance prevalence. Results: Among the 905 records, 59 studies spanning 21 countries (1976 to 2024) met the inclusion criteria. The prevalence of cotrimoxazole resistance, based on 3,756 isolates, was 0.034 (95% CI, 0.017, 0.068), with increasing trends over time, especially in B. melitensis. Rifampin resistance, involving 3,938 isolates, had a prevalence of 0.046 (95% CI, 0.027, 0.077), showing temporal and species-specific increases. Subgroup analyses revealed significant variations in resistance based on temporal, geographical, and guideline-related factors. Conclusions: This systematic review and meta-analysis highlighted an alarming rise in cotrimoxazole and rifampin resistance in B. abortus and B. melitensis, particularly in pediatric brucellosis. Temporal, geographical, and species-specific variations underscore the dynamic nature of antibiotic resistance, emphasizing the need for targeted interventions, surveillance, and global collaboration to preserve the efficacy of essential antibiotics in brucellosis treatment. The limitations include potential biases and the retrospective nature of the included studies, emphasizing the urgent need for standardized surveillance methodologies and robust reporting mechanisms.
- 2 December 2024
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 18 (12) , e0012630
Open AccessUnravelling the challenge of cotrimoxazole and rifampin resistance in B. melitensis and B. abortus: A systematic review and meta-analysis
Background: Brucellosis caused by Brucella (B. abortus) and Brucella melitensis (B. melitensis) poses a significant threat to human and animal populations. The World Health Organization (WHO) recommends rifampin and cotrimoxazole as first-line treatments for pediatric brucellosis. However, emerging resistance to these antibiotics raises concerns regarding their continued efficacy. This systematic review and meta-analysis aimed to quantitatively assess the prevalence of rifampin and cotrimoxazole resistance in B. abortus and B. melitensis. Methods: Eligible studies were identified by systematically searching various databases, such as Scopus, PubMed, Web of Science, and EMBASE databases, using specified search terms until 18 June 2024. The inclusion criteria required studies in English to report the resistance proportion with sample size details. The meta-analysis utilized a random-effects model to assess heterogeneity using the Q-test and I2 statistic. Meta-regression and subgroup analyses explored temporal, geographical, and guideline-related variations in resistance prevalence. Results: Among the 905 records, 59 studies spanning 21 countries (1976 to 2024) met the inclusion criteria. The prevalence of cotrimoxazole resistance, based on 3,756 isolates, was 0.034 (95% CI, 0.017, 0.068), with increasing trends over time, especially in B. melitensis. Rifampin resistance, involving 3,938 isolates, had a prevalence of 0.046 (95% CI, 0.027, 0.077), showing temporal and species-specific increases. Subgroup analyses revealed significant variations in resistance based on temporal, geographical, and guideline-related factors. Conclusions: This systematic review and meta-analysis highlighted an alarming rise in cotrimoxazole and rifampin resistance in B. abortus and B. melitensis, particularly in pediatric brucellosis. Temporal, geographical, and species-specific variations underscore the dynamic nature of antibiotic resistance, emphasizing the need for targeted interventions, surveillance, and global collaboration to preserve the efficacy of essential antibiotics in brucellosis treatment. The limitations include potential biases and the retrospective nature of the included studies, emphasizing the urgent need for standardized surveillance methodologies and robust reporting mechanisms.
- Open Access
- 23 August 2024
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 39, 82-91
Prevalence of antibiotic-resistant Cutibacterium acnes (formerly Propionibacterium acnes) isolates, a systematic review and meta-analysis
- 23 August 2024
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 39, 82-91
Open AccessPrevalence of antibiotic-resistant Cutibacterium acnes (formerly Propionibacterium acnes) isolates, a systematic review and meta-analysis
- 1 June 2020
- Published by CMV Verlag in Alborz University Medical Journal
- Vol. 9 (3) , 335-344
The Effects of Dr Kamkar’s Herbal Cream in Healing Stage One to Third Pressure Ulcer
- 1 June 2020
- Published by CMV Verlag in Alborz University Medical Journal
- Vol. 9 (3) , 335-344
The Effects of Dr Kamkar’s Herbal Cream in Healing Stage One to Third Pressure Ulcer